Purpose We evaluated the efficacy and toxicity of mammalian target rapamycin inhibitors in Korean patients with metastatic renal cell carcinoma (mRCC) with chronic renal insufficiency not requiring dialysis. Materials and Methods Korean patients with mRCC and chronic renal insufficiency not requiring dialysis treated with everolimus or temsirolimus between January 2008 and December 2014 were included. Patient characteristics, clinical outcomes, and toxicities were evaluated. Overall survival (OS) and progression-free survival (PFS) durations were evaluated according to the degree of renal impairment.
Results Eighteen patients were considered eligible for the study (median age, 59 years). The median glomerular filtration rate was 51.5 mL/min/1.73 m2. The best response was partial response in six patients and stable disease in 11 patients. The median PFS and OS durations were 8 months (95% confidence interval [CI], 0 to 20.4) and 32 months (95% CI, 27.5 to 36.5), respectively. The most common non-hematologic and grade 3/4 adverse events included stomatitis, fatigue, flu-like symptoms, and anorexia as well as elevated creatinine level. Conclusion Mammalian target rapamycin inhibitors were efficacious and did not increase toxicity in Korean patients with mRCC and chronic renal insufficiency not requiring dialysis.
Citations
Citations to this article as recorded by
Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: A systematic review and meta-analysis Manuel Eros Rodríguez-Fuentes, Mario Pérez-Sayáns, Carmen Martín Carreras-Presas, Xabier Marichalar-Mendia, Leticia Bagán-Debón, Rafael López-López Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2023; 135(3): 385. CrossRef
Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function Łukasz Mielczarek, Anna Brodziak, Paweł Sobczuk, Maciej Kawecki, Agnieszka Cudnoch-Jędrzejewska, Anna M. Czarnecka Cancer Chemotherapy and Pharmacology.2021; 87(6): 723. CrossRef
Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study Cristina Masini, Maria Giuseppa Vitale, Marco Maruzzo, Giuseppe Procopio, Ugo de Giorgi, Sebastiano Buti, Sabrina Rossetti, Roberto Iacovelli, Francesco Atzori, Laura Cosmai, Francesca Vignani, Giuseppe Prati, Sarah Scagliarini, Annalisa Guida, Annalisa B Clinical Genitourinary Cancer.2019; 17(1): e150. CrossRef
Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials Ravi K. Paluri, Guru Sonpavde, Charity Morgan, Jacob Rojymon, Anastasia Hartzes Mar, Radhika Gangaraju Oncology Reviews.2019;[Epub] CrossRef
von Hippel–Lindau (VHL) disease is an autosomal dominant inherited tumor syndrome associated with mutations of the VHL tumor suppressor gene located on chromosome 3p25. The loss of functional VHL protein contributes to tumorigenesis. This condition is characterized by development of benign and malignant tumors in the central nervous system (CNS) and the internal organs, including kidney, adrenal gland, and pancreas. We herein describe the case of a 74-year-old man carrying the VHL gene mutation who was affected by simultaneous colorectal adenocarcinoma, renal clear cell carcinoma, and hemangioblastomas of CNS.
Citations
Citations to this article as recorded by
Diversities of Mechanism in Patients with VHL Syndrome and diabetes: A Report of Two Cases and Literature Review Yanlei Wang, Zhaoxiang Liu, Wenhui Zhao, Chenxiang Cao, Luqi Xiao, Jianzhong Xiao Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 1611. CrossRef
Sporadic Renal Hemangioblastoma: A Case Report of a Rare Entity Fnu Raja, Vinesh Kumar, Azzam Hammad, Caroline Abramovich Cureus.2023;[Epub] CrossRef
VHL syndrome without clear family history: A rare case report and literature review of Chinese patients Yaheng Li, Xiaohong Xin, Wenzhu Song, Xuan Zhang, Shengli Chen, Qian Wang, Aizhong Li, Yafeng Li Frontiers in Neurology.2022;[Epub] CrossRef
Von Hipple-Lindau disease complicated with central retinal vein occlusion: a case report Xingwang Chen, Mengyao Wang, Yuan Tang, Bing Xie, Xiaomei Nie, Shanjun Cai BMC Ophthalmology.2022;[Epub] CrossRef
Whole-Exome Sequencing Reveals Novel Variations in Patients with Familial Von Hippel−Lindau Syndrome Yuhao Zhou, Jian Liu, Liangzhao Chu, Minghao Dong, Luqian Feng World Neurosurgery.2021; 150: e696. CrossRef
Sporadic renal hemangioblastoma: A case report of a rare benign renal tumor Lukas Oberhammer, Michael Josef Mitterberger, Lukas Lusuardi, Thomas Kunit, Martin Drerup, Daniela Colleselli, Hubert Griessner, Martina Hager Clinical Case Reports.2019; 7(12): 2321. CrossRef
MicroRNA Assisted Gene Regulation in Colorectal Cancer Adewale Fadaka, Ashley Pretorius, Ashwil Klein International Journal of Molecular Sciences.2019; 20(19): 4899. CrossRef
Choong-kun Lee, Minkyu Jung, Hye Jin Choi, Hye Ryun Kim, Hyo Song Kim, Mi Ryung Roh, Joong Bae Ahn, Hyun Cheol Chung, Su Jin Heo, Sun Young Rha, Sang Joon Shin
Cancer Res Treat. 2015;47(4):781-789. Published online February 16, 2015
Purpose There is no standard second-line regimen for malignant melanoma patients with disease progression after first-line chemotherapy, and platinum-alkylating agents combined with paclitaxel have shown modest efficacy. Materials and Methods We conducted a phase II, open-label, single-arm study to test the efficacy of docetaxel combined with carboplatin for malignant melanoma patients who failed previous treatment with dacarbazine. Intravenous docetaxel (35 mg/m2 on days 1 and 8 of each cycle) and carboplatin (area under the curve 3 on days 1 and 8 of each cycle) was administered every 21 days. Primary end point was objective response rate (ORR).
Results Thirty patients were enrolled in the study, and the median follow-up duration was 19.8 months. Among 25 per-protocol patients, there were three responders (1 with complete response and 2 with partial response) and 17 stable disease patients (ORR, 12.0%). Among the per-protocol population, the median progression-free survival (PFS) was 4.3 months and the median overall survival (OS) was 9.6 months. Uveal melanoma patients (n=9) showed the best prognosis compared to other subtypes (median PFS, 7.6 months; OS, 9.9 months). The most common grade 3 or 4 adverse event was neutropenia (n=15, 50.0%). Conclusion Docetaxel combined with carboplatin showed association with an acceptable safety profile and overall efficacy for patients with malignant melanoma who had progressed on chemotherapy containing dacarbazine.
Citations
Citations to this article as recorded by
Signaling pathways driving ocular malignancies and their targeting by bioactive phytochemicals Courtney R. Croley, Joshua Pumarol, Blake E. Delgadillo, Andrew C. Cook, Faith Day, Tea Kaceli, Caroline C. Ward, Imran Husain, Ali Husain, Sabyasachi Banerjee, Anupam Bishayee Pharmacology & Therapeutics.2023; 248: 108479. CrossRef
A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma Pui Ying Chan, Melissa M. Phillips, Stephen Ellis, Amanda Johnston, Xiaoxing Feng, Amit Arora, Gordon Hay, Victoria M. L. Cohen, Mandeep S. Sagoo, John S. Bomalaski, Michael T. Sheaff, Peter W. Szlosarek Pigment Cell & Melanoma Research.2022; 35(4): 461. CrossRef
iUMRG: multi-layered network-guided propagation modeling for the inference of susceptibility genes and potential drugs against uveal melanoma Yueping Ren, Congcong Yan, Lili Wu, Jingting Zhao, Mingwei Chen, Meng Zhou, Xiaoyan Wang, Tonghua Liu, Quanyong Yi, Jie Sun npj Systems Biology and Applications.2022;[Epub] CrossRef
Systemic and Liver-Directed Therapies in Metastatic Uveal Melanoma: State-of-the-Art and Novel Perspectives Francesca Comito, Paola Valeria Marchese, Angela Dalia Ricci, Nastassja Tober, Chiara Peterle, Francesca Sperandi, Barbara Melotti Future Oncology.2021; 17(33): 4583. CrossRef
New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review Mario Damiano Toro, Lucia Gozzo, Luciano Tracia, Marco Cicciù, Filippo Drago, Claudio Bucolo, Teresio Avitabile, Robert Rejdak, Katarzyna Nowomiejska, Sandrine Zweifel, Yacoub A. Yousef, Rashed Nazzal, Giovanni Luca Romano Biomedicines.2021; 9(10): 1311. CrossRef
Interferon-α versus interleukin-2 in Chinese patients with malignant melanoma Shenglong Li, Xixi Wu, Peng Chen, Yi Pei, Ke Zheng, Wei Wang, Enduo Qiu, Xiaojing Zhang Anti-Cancer Drugs.2019; 30(4): 402. CrossRef
Mechanism of HN‑3 cell apoptosis induced by carboplatin: Combination of mitochondrial pathway associated with Ca2+ and the nucleus pathways Bo Shen, Wenjing Mao, Jin‑Chul Ahn, Phil‑Sang Chung, Peijie He Molecular Medicine Reports.2018;[Epub] CrossRef
Endoplasmic reticulum stress-mediated pathways to both apoptosis and autophagy: Significance for melanoma treatment Mohamed Hassan World Journal of Experimental Medicine.2015; 5(4): 206. CrossRef